ASMB Quote, Trading Chart, Assembly Biosciences Inc.
home / stock / asmb / asmb quote
$5.05 Last:
-0.59% Change Percent:
$5.1493 Open:
$5.05 Previous Close:
$5.23 High:
$5.02 Low:
1,835,177 Volume:
03/01/2021 04:55:13 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-01 | 5.1493 | 5.05 | 5.23 | 5.02 | 1,835,177 |
| 2021-02-26 | 5.2139 | 5.08 | 5.54 | 5.07 | 2,384,627 |
| 2021-02-25 | 5.68 | 5.53 | 5.83 | 5.41 | 2,294,002 |
| 2021-02-24 | 5.64 | 5.64 | 5.69 | 5.47 | 1,464,203 |
| 2021-02-23 | 5.6 | 5.46 | 5.63 | 5.25 | 1,980,538 |
| 2021-02-22 | 5.81 | 5.73 | 5.96 | 5.7 | 1,487,440 |
| 2021-02-19 | 5.86 | 5.83 | 6.08 | 5.83 | 1,764,838 |
| 2021-02-18 | 6.01 | 5.79 | 6.02 | 5.75 | 1,254,142 |
| 2021-02-17 | 6.18 | 6.09 | 6.2 | 6 | 1,096,931 |
| 2021-02-16 | 6.31 | 6.14 | 6.34 | 6.03 | 1,616,261 |
| 2021-02-15 | 6.36 | 6.29 | 6.3901 | 6.18 | 935,032 |
| 2021-02-12 | 6.36 | 6.29 | 6.3901 | 6.18 | 927,236 |
| 2021-02-11 | 6.59 | 6.37 | 6.62 | 6.22 | 2,078,993 |
| 2021-02-10 | 7.0081 | 6.59 | 7.02 | 6.25 | 2,991,369 |
| 2021-02-09 | 6.62 | 6.63 | 7 | 6.57 | 3,311,790 |
| 2021-02-08 | 6.28 | 6.45 | 6.49 | 6.19 | 2,866,596 |
| 2021-02-05 | 6.19 | 6.15 | 6.2575 | 6.075 | 1,132,166 |
| 2021-02-04 | 6.07 | 6.12 | 6.16 | 6.01 | 1,907,452 |
| 2021-02-03 | 5.89 | 6.01 | 6.01 | 5.85 | 1,456,185 |
| 2021-02-02 | 5.83 | 5.84 | 5.88 | 5.74 | 1,194,122 |
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasd...
-
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the fourth quarte...
-
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call toda...
Important Investor News Alert (OTCMKTS: GTCH)
-
Point Roberts, WA and Vancouver, BC - February 26, 2021 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and adva...